<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">More recently, the development of clevudine as a treatment for CHB was terminated because of case reports of myopathy
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>
 </sup>. Fleischer RD 
 <italic>et al</italic>. found that the drug was not incorporated into mtDNA and was not an inhibitor or a substrate for DNA polymerase; therefore, mitochondrial toxicity was not expected
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>,
  <xref ref-type="bibr" rid="CR27">27</xref>
 </sup>. However, mitochondrial toxicity may arise not only from inhibition of DNA polymerase, but also from mtDNA mutations and mitochondrial oxidative stress
 <sup>
  <xref ref-type="bibr" rid="CR26">26</xref>,
  <xref ref-type="bibr" rid="CR28">28</xref>
 </sup>.
</p>
